Table 3 Comparison of users of menthol vs. non-menthol flavored electronic cigarettes in COPDGene study

N (sample size)

94

69

25

Age, years

65.2 (6.3)

65.6 (6.6)

64.1 (5.5)

Gender, %

 Male

44.7%

46.4%

40.0%

 Female

55.3%

53.6%

60.0%

Race, %

 Caucasian

67.0%

69.6%

60.0%

 African American

33.0%

30.4%

40.0%

Current tobacco smoking, %

56.4%

53.6%

64.0%

Years since quitting tobacco

4.0 (2.0–6.0)

4.0 (1.5–6.0)

5.0 (4.0–7.0)

Pack-years of tobacco smoking

43.3 (30.8–57.5)

43.4 (30.8–55.8)

43.2 (31.2–57.5)

Duration of smoking tobacco, years

46.0 (42.0–50.7)

47.0 (42.4–51.0)

45.0 (41.0–48.2)

Average cigarettes/day, last 5 years

10.0 (8.0–20.0)

10.0 (8.0–20.0)

11.0 (6.0–20.0)

Resting oxygen saturation, %

96.3 (2.5)

96.2 (2.5)

96.6 (2.5)

Body mass index, kg/m²

29.2 (6.7)

29.2 (6.8)

29.1 (6.5)

MMRC dyspnea score

 0

53.2%

49.3%

64.0%

 1

6.4%

7.2%

4.0%

 2

13.8%

17.4%

4.0%

 3

21.3%

21.7%

20.0%

 4

5.3%

4.3%

8.0%

St George's Respiratory Questionnaire

19.2 (7.2–43.0)

18.4 (9.8–41.6)

19.9 (6.5–49.1)

Duration of e-cig use, months

12 (22)

12 (20)

12 (34)

E-cig contains nicotine

71.3%

66.7%

84.0%

E-cig contains cannabis

12.8%

17.4%

0.0%

FEV1, % predicted

80.1 (21.7)

82.8 (20.9)

72.9 (22.7)

FEV1/FVC

0.69 (0.12)

0.70 (0.12)

0.65 (0.12)

Bronchodilator response, %

13.8%

15.9%

8.0%

Spirometric GOLD stage

 PRISM

14.9%

13.0%

20.0%

 GOLD 0

54.3%

56.5%

48.0%

 GOLD 1

5.3%

2.9%

12.0%

 GOLD 2

16.0%

15.9%

16.0%

 GOLD 3

5.3%

5.8%

4.0%

Percent emphysema (LAA% − 950)

2.2 (0.8–5.6)

2.4 (0.8–5.6)

1.6 (0.8–5.4)

% Gas trapping

12.7 (5.1–30.0)

11.1 (5.0–27.9)

19.5 (10.4–35.0)